Compare CSTL & CGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSTL | CGC |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 661.7M | 578.3M |
| IPO Year | 2019 | N/A |
| Metric | CSTL | CGC |
|---|---|---|
| Price | $39.29 | $1.21 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 2 |
| Target Price | ★ $42.83 | N/A |
| AVG Volume (30 Days) | 370.2K | ★ 53.7M |
| Earning Date | 11-03-2025 | 02-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $343,530,000.00 | $200,022,256.00 |
| Revenue This Year | $1.69 | $6.79 |
| Revenue Next Year | N/A | $7.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 10.15 | N/A |
| 52 Week Low | $14.59 | $0.77 |
| 52 Week High | $42.18 | $3.07 |
| Indicator | CSTL | CGC |
|---|---|---|
| Relative Strength Index (RSI) | 58.67 | 44.98 |
| Support Level | $37.76 | $1.54 |
| Resistance Level | $42.18 | $2.38 |
| Average True Range (ATR) | 1.20 | 0.26 |
| MACD | -0.35 | -0.04 |
| Stochastic Oscillator | 46.17 | 8.91 |
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
Canopy Growth Corp, cultivates and sells medicinal and recreational cannabis and hemp through a portfolio of brands that include Doja, LivRelief, Ace Valley, Deep Space, and others. The Company is engaged in reportable segments namely: Canada cannabis, International markets cannabis, Storz & Bickel, and This Works. The company generates maximum revenue from Canadian cannabis.